agilon Reports Q4 Revenue of $1.57B, Beating Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy AGL?
Reports Q4 revenue $1.57B, consensus $1.46B. Total members on the agilon platform decreased to 625,000 as of December 31, 2025, comprising 511,000 Medicare Advantage members and 114,000 ACO model beneficiaries. Year-over-year changes to membership reflect previously disclosed market exits. "2025 was a pivotal year for agilon. We confronted challenges head-on and focused our actions to accelerate meaningful transformation across the company - enhancing execution, improving operating discipline, and fundamentally strengthening the economics of our model," stated Ronald A. Williams, Executive Chair. "While we were not satisfied by our 2025 financial performance, the transformation initiatives are delivering tangible benefits which support our expectation for material improvement in 2026. Based on the progress we have made and the momentum we are carrying into 2026, I am confident in our trajectory and firmly believe agilon and our partners are entering the next phase with a stronger foundation, a more resilient model, and a clear path to sustainable value creation."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGL
Wall Street analysts forecast AGL stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.616
Low
0.88
Averages
0.88
High
0.88
Current: 0.616
Low
0.88
Averages
0.88
High
0.88
About AGL
agilon health, inc. is a healthcare company. It enables primary care physicians (PCP) to be the agents for change in the communities they serve. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of its physician partners’ attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform is holistic in supporting the rapid transition to a Total Care Model with technology, people, process and capital.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Potential Claims Against Agilon Health
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Agilon Health, reminding investors to seek lead plaintiff status by March 2, 2026, indicating significant legal risks for the company.
- False Statement Allegations: The lawsuit alleges that Agilon and its executives violated federal securities laws by issuing misleading guidance for 2025, resulting in investor losses when the truth emerged.
- Stock Price Plunge: Following Agilon's August 4, 2025 press release announcing the suspension of its 2025 financial guidance, the stock plummeted 51.5% the next day, reflecting market disappointment in the company's outlook.
- Investor Rights Protection: Faruq & Faruq encourages anyone with information regarding Agilon's conduct to contact the firm, highlighting potential liabilities the company may face in the ongoing litigation and the rights of investors to seek recovery.
See More
Agilon Health Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Agilon Health for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and August 4, 2025, with a deadline to contact the firm by March 2, 2026.
- False Statements Allegation: The complaint alleges that Agilon made false and misleading statements regarding its 2026 guidance, which was beyond its capabilities, and overstated the effectiveness of its strategic actions to mitigate risks, resulting in investor losses when the truth emerged.
- Legal Representation Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially forfeiting their rights to recover losses.
- Investor Rights Advocacy: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, urging affected investors to join the lawsuit to seek compensation for their losses, highlighting its commitment to protecting investor rights globally.
See More
Class Action Lawsuit Filed Against Agilon Health, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. announces a class action lawsuit against Agilon Health, Inc. on behalf of investors who purchased securities between February 26, 2025, and August 4, 2025, alleging that the company made false and misleading statements during this period, resulting in investor losses.
- Allegation Details: The lawsuit claims that Agilon's management issued unrealistic 2025 financial guidance despite being aware of significant industry challenges and overstated the immediate financial benefits from strategic actions, misleading investors about the company's business prospects.
- Investor Rights: Affected investors must apply by March 2, 2026, to be appointed as lead plaintiff in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging investors to reach out for more information.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in representing individual and institutional investors in securities, derivative, and commercial litigation, with extensive litigation experience and a nationwide practice.
See More
Faruqi & Faruqi Investigates Agilon Health Securities Fraud Case
- Legal Investigation Launched: Faruq & Faruqi is investigating Agilon Health's securities transactions between February 26 and August 4, 2025, alleging that the company and its executives violated federal securities laws, resulting in investor losses.
- Misguided Financial Guidance: The lawsuit claims that Agilon Health's 2025 financial guidance was materially misleading as it failed to disclose the impact of industry headwinds, leading to investor losses when the true situation emerged.
- Stock Price Plunge: Following the release of its Q2 2025 results on August 4, Agilon Health announced the suspension of its 2025 financial guidance, causing its stock to plummet by 51.5% the next day, reflecting market disappointment in the company's outlook.
- Investor Rights Protection: Faruq & Faruqi reminds investors that March 2 is the deadline to apply to become the lead plaintiff in the class action lawsuit, encouraging affected investors to contact the firm to discuss their legal rights.
See More
Notice of Securities Class Action for Agilon Health
- Class Action Notice: Rosen Law Firm reminds investors who purchased Agilon Health securities between February 26, 2025, and August 4, 2025, that they must apply to be lead plaintiff by March 2, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, ensuring that investors can seek compensation without additional financial burden.
- Lawsuit Background: The lawsuit alleges that Agilon Health made false and misleading statements during the class period, resulting in investor losses when the true financial situation became known, highlighting the company's failure to disclose its financial challenges amid industry headwinds.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Class Action Lawsuit Filed Against Agilon Health
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Agilon Health, alleging violations of federal securities laws by the company and its officers from February 26, 2025, to August 4, 2025, seeking to recover damages for investors.
- False Statement Allegations: The complaint claims that throughout the class period, defendants made false and misleading statements and failed to disclose significant industry headwinds affecting their 2026 financial guidance, leading to investor misconceptions about the company's prospects.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by March 2, 2026, to share in any potential recovery from the lawsuit, with no requirement to serve as lead plaintiff to participate in any compensation.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing its role in upholding market integrity.
See More
Faruqi & Faruqi Investigates Potential Claims Against Agilon Health
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Agilon Health, reminding investors to seek lead plaintiff status by March 2, 2026, indicating significant legal risks for the company.
- False Statement Allegations: The lawsuit alleges that Agilon and its executives violated federal securities laws by issuing misleading guidance for 2025, resulting in investor losses when the truth emerged.
- Stock Price Plunge: Following Agilon's August 4, 2025 press release announcing the suspension of its 2025 financial guidance, the stock plummeted 51.5% the next day, reflecting market disappointment in the company's outlook.
- Investor Rights Protection: Faruq & Faruq encourages anyone with information regarding Agilon's conduct to contact the firm, highlighting potential liabilities the company may face in the ongoing litigation and the rights of investors to seek recovery.
See More
Agilon Health Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Agilon Health for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and August 4, 2025, with a deadline to contact the firm by March 2, 2026.
- False Statements Allegation: The complaint alleges that Agilon made false and misleading statements regarding its 2026 guidance, which was beyond its capabilities, and overstated the effectiveness of its strategic actions to mitigate risks, resulting in investor losses when the truth emerged.
- Legal Representation Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially forfeiting their rights to recover losses.
- Investor Rights Advocacy: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, urging affected investors to join the lawsuit to seek compensation for their losses, highlighting its commitment to protecting investor rights globally.
See More
Class Action Lawsuit Filed Against Agilon Health, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. announces a class action lawsuit against Agilon Health, Inc. on behalf of investors who purchased securities between February 26, 2025, and August 4, 2025, alleging that the company made false and misleading statements during this period, resulting in investor losses.
- Allegation Details: The lawsuit claims that Agilon's management issued unrealistic 2025 financial guidance despite being aware of significant industry challenges and overstated the immediate financial benefits from strategic actions, misleading investors about the company's business prospects.
- Investor Rights: Affected investors must apply by March 2, 2026, to be appointed as lead plaintiff in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging investors to reach out for more information.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in representing individual and institutional investors in securities, derivative, and commercial litigation, with extensive litigation experience and a nationwide practice.
See More
Faruqi & Faruqi Investigates Agilon Health Securities Fraud Case
- Legal Investigation Launched: Faruq & Faruqi is investigating Agilon Health's securities transactions between February 26 and August 4, 2025, alleging that the company and its executives violated federal securities laws, resulting in investor losses.
- Misguided Financial Guidance: The lawsuit claims that Agilon Health's 2025 financial guidance was materially misleading as it failed to disclose the impact of industry headwinds, leading to investor losses when the true situation emerged.
- Stock Price Plunge: Following the release of its Q2 2025 results on August 4, Agilon Health announced the suspension of its 2025 financial guidance, causing its stock to plummet by 51.5% the next day, reflecting market disappointment in the company's outlook.
- Investor Rights Protection: Faruq & Faruqi reminds investors that March 2 is the deadline to apply to become the lead plaintiff in the class action lawsuit, encouraging affected investors to contact the firm to discuss their legal rights.
See More
Notice of Securities Class Action for Agilon Health
- Class Action Notice: Rosen Law Firm reminds investors who purchased Agilon Health securities between February 26, 2025, and August 4, 2025, that they must apply to be lead plaintiff by March 2, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, ensuring that investors can seek compensation without additional financial burden.
- Lawsuit Background: The lawsuit alleges that Agilon Health made false and misleading statements during the class period, resulting in investor losses when the true financial situation became known, highlighting the company's failure to disclose its financial challenges amid industry headwinds.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Class Action Lawsuit Filed Against Agilon Health
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Agilon Health, alleging violations of federal securities laws by the company and its officers from February 26, 2025, to August 4, 2025, seeking to recover damages for investors.
- False Statement Allegations: The complaint claims that throughout the class period, defendants made false and misleading statements and failed to disclose significant industry headwinds affecting their 2026 financial guidance, leading to investor misconceptions about the company's prospects.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by March 2, 2026, to share in any potential recovery from the lawsuit, with no requirement to serve as lead plaintiff to participate in any compensation.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing its role in upholding market integrity.
See More
